Resveratrol, a natural product derived from grape, exhibits antiestrogenic activity and inhibits the growth of human breast cancer cells

Journal of Cellular Physiology

Volumn 179, Issue 3, 1999, Pages 297-304

  Lu, Runqing ^a   Serrero, Ginette ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ESTROGEN; ESTROGEN RECEPTOR; MESSENGER RNA; NATURAL PRODUCT; PROGESTERONE RECEPTOR; RESVERATROL; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA2;

ARTICLE; BREAST CANCER; CANCER CELL; DOSE RESPONSE; DRUG EFFECT; GENE ACTIVATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CELL DIVISION; CULTURE MEDIA; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; ESTROGEN ANTAGONISTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; RECEPTOR, IGF TYPE 1; RNA, MESSENGER; ROSALES; STILBENES; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR CELLS, CULTURED;

MINK CELL FOCUS-FORMING VIRUS; VITACEAE; VITIS SP.;

EID: 0032913414     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4652(199906)179:3<297::AID-JCP7>3.0.CO;2-P     Document Type: Article

References (53)

1. Adlercreutz H, Mousavi Y, Clark J, Hockerstedt K, Hamalainen E, Wahala K, Makela T, Hase T. 1992. Dietary phytoestrogens and cancer: in vitro and in vivo studies. J Steroid Biochem Mol Biol 41:331-337.
2. Arrick BA, Korc M, Derynck R. 1990. Differential regulation of expression of three transforming growth factor beta species in human breast cancer cell lines by estradiol. Cancer Res 50:299-303.
3. Arteaga CL, Coffey RJ Jr, Dugger TC, McCutchen CM, Moses HL, Lyons RM. 1990. Growth stimulation of human breast cancer cells with anti-transforming growth factor beta antibodies: evidence for negative autocrine regulation by transforming growth factor beta. Cell Growth Differ 1:367-374.
4. Butta A, MacLennan K, Flanders KC, Sacks NP, Smith I, McKinna A, Dowsett M, Wakefield LM, Sporn MB, Baum M, Colletta AA. 1992. Induction of transforming growth factor beta 1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res 52:4261-4264.
5. Clement MV, Hirpara JL, Chawdhury SH, Pervaiz S. 1998. Chemopreventive agent resveratrol, a natural product derived from grapes, triggers CD95 signaling-dependent apoptosis in human tumor cells. Blood 92:996-1002.
6. Collins BM, McLachlan JA, Arnold SF. 1997. The estrogenic and antiestrogenic activities of phytochemicals with the human estrogen receptor expressed in yeast. Steroids 62:365-372.
7. Dercks W, Creasy LL. 1989. Influence of fosetyl-AL on phytoalexin accumulation in the plasmopara viticola-grapevine interaction. Physiol Mol Plant Pathol 34:203-213.
8. Dickson RB. 1990. Stimulatory and inhibitory growth factors and breast cancer. J Steroid Biochem Mol Biol 37:795-803.
9. Dickson RB, Lippman ME. 1995. Growth factors in breast cancer. Endocr Rev 16:559-589.
10. Eisinger DP, Serrero G. 1993. Structure of the gene encoding mouse adipose differentiation-related protein (ADRP). Genomics 16:638-644.
11. Fang N, Casida JE. 1998. Anticancer action of cube insecticide: correlation for rotenoid constituents between inhibition of NADH: ubiquinone oxidoreductase and induced ornithine decarboxylase activities, Proc Natl Acad Sci USA 95:3380-3384.
12. Fontecave M, Lepoivre M, Elleingand E, Gerez C, Guittet O. 1998. Resveratrol, a remarkable inhibitor of ribonucleotide reductase. FEBS Lett 421:277-279.
13. Frankel EN, Waterhouse AL, Kinsella JE. 1993. Inhibition of human LDL oxidation by resveratrol. Lancet 341:1103-1104.
14. Gehm BD, McAndrews JM, Chien PY, Jameson JL. 1997. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc Natl Acad Sci USA 94:14138-14143.
15. Gronbaek M, Deis A, Sorensen IT, Becker U, Schnohr P, Jensen G. 1995. Mortality associated with moderate intakes of wine, beer, or spirits. Br Med J 310:1165-1169.
16. st Ed. New York: Van Nostrand Reinhold Co.
17. Hobisch A, Hittmair A, Daxenbichler G, Wille S, Radmayr C, Hobischhagen P, Bartsch G, Klocker H, Culig Z. 1997. Metastatic lesions from prostate cancer do not express oestrogen and progesterone receptors. J Pathol 182:356-361.
18. Ide H, Yoshida T, Matsumoto N, Aoki K, Osada Y, Sugimura T, Terada M. 1997. Growth regulation of human prostate cancer cells by bone morphogenetic protein-2. Cancer Res 57:5022-5027.
19. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HHS, Farnsworth NR, Kinghorn AD, Mehta RG, Moon RC, Pezzuto JM. 1997. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275:218-220.
20. Jeng M-H, Dijke PT, Iwata KK, Jordan VC. 1993. Regulation of the levels of three transforming growth factor beta mRNAs by estrogen and their effects on the proliferation of human breast cancer cells. Mol Cell Endocrinol 97:115-123.
21. Jones JI, Clemmons DR. 1995. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 16:3-34.
22. Katzenellenbogen BS, Kendra KL, Norman MJ, Berthois Y. 1987. Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cell growth in the short-term and long-term absence of estrogens. Cancer Res 47:4355-4360.
23. Knabbe C, Lippman ME, Wakefield LM, Flanders KC, Kasid A, Derynck R, Dickson RB. 1987. Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell 48:417-428.
24. Knabbe C, Kopp A, Hilgers W, Lang D, Muller V, Zugmaier G, Jonat W. 1996. Regulation and role of TGF beta production in breast cancer. Ann NY Acad Sci 784:263-276.
25. Koli KM, Ramsey TT, Ko Y, Dugger TC, Brattain MG, Arteaga CL. 1997. Blockade of transforming growth factor-beta signaling does not abrogate antiestrogen-induced growth inhibition of human breast carcinoma cells. J Biol Chem 272:8296-8320.
26. Kopp A, Jonat W, Schmahl M, Knabbe C. 1995. Transforming growth factor beta 2 (TGF-beta 2) levels in plasma of patients with metastatic breast cancer treated with tamoxifen. Cancer Res 55:4512-4515.
27. Lippman ME, Dickson RB. 1989. Mechanisms of growth control in normal and malignant breast epithelial growth regulation. Recent Prog Horm Res 45:383-440.
28. Lippman ME, Dickson RB, Gelmann EP, Rosen N, Knabbe C, Bates S, Bronzert D, Huff KM, Kasid A. 1988. Growth regulatory peptide production by human breast carcinoma cells. J Steroid Biochem 30:53-61.
29. MacCallum J, Keen JC, Bartlett JM, Thompson AM, Dixon JM, Miller WR. 1996. Changes in expression of transforming growth factor beta mRNA isoforms in patients undergoing tamoxifen therapy. Br J Cancer 74:474-478.
30. Makela SI, Pylkkanen LH, Santti RS, Adlercreutz H. 1995a. Dietary soybean may be antiestrogenic in male mice. J Nutr 125:437-445.
31. Makela S, Santti R, Salo L, McLachlan JA. 1995b. Phytoestrogens are partial estrogen agonists in the adult male mouse. Environ Health Perspect 103(suppl) 7:123-127.
32. Markaverich BM, Webb B, Densmore CL, Gregory RR. 1995. Effects of coumestrol on estrogen receptor function and uterine growth in ovariectomized rats. Environ Health Perspect 103:574-581.
33. May FE, Westley BR. 1995. Estrogen regulated messenger RNAs in human breast cancer cells. Biomed Pharmacother 49:400-414.
34. May FE, Johnson MD, Wiseman LR, Wakeling AE, Kastner P, Westley BR. 1989. Regulation of progesterone receptor mRNA by oestradiol and antiestrogens in breast cancer cell lines. J Steroid Biochem 33:1035-1041.
35. st Ed. New York: Elsevier.
36. Mgbonyebi OP, Russo J, Russo IH. 1998. Antiproliferative effect of synthetic resveratrol on human breast epithelial cells. Int J Oncol 12:865-869.
37. Miksicek RJ. 1993. Commonly occurring plant flavonoids have estrogenic activity. Mol Pharmacol 44:37-43.
38. Mousavi Y, Adlercreutz H. 1992. Enterolactone and estradiol inhibit each other's proliferative effect on MCF-7 breast cancer cells in culture. J Steroid Biochem Mol Biol 41:615-619.
39. Muller V, Jensen EV, Knabbe C. 1998. Partial antagonism between steroidal and nonsteroidal antiestrogens in human breast cancer cell lines. Cancer Res 58:263-267.
40. Quinn KA, Treston AM, Unsworth EJ, Miller MJ, Vos M, Grimley C, Battey J, Mulshine J, Cuttitta F. 1996. Insulin-like growth factor expression in human cancer cell lines. J Biol Chem 271:11477-11483.
41. Renaud S, de Lorgeril M. 1993. The French paradox: dietary factors and cigarette smoking-related health risks. Ann NY Acad Sci 686:299-309.
42. Ruh MF, Zacharewski T, Connor K, Howell J, Chen I, Safe S. 1995. Naringenin: a weakly estrogenic bioflavonoid that exhibits antiestrogenic activity. Biochem Pharmacol 50:1485-1493.
43. Russo J, Gusterson BA, Rogers AE, Russo IH, Wellings SR, van Zwieten MJ. 1990. Comparative study of human and rat mammary tumorigenesis. Lab Invest 62:244-278.
44. st Ed. London: Academic Press.
45. Soleas GJ, Diamandis EP, Goldberg DM. 1997. Resveratrol; a molecule whose time has come? and gone? Clin Biochem 30:91-113.
46. Spicer AP, Rowse GJ, Lidner TK, Gendler SJ. 1995. Delayed mammary tumor progression in Muc-1 null mice. J Biol Chem 270:30093-30101.
47. Stewart A, Johnson MD, May FE, Westley BR. 1990. Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. J Biol Chem 265:21172-21178.
48. Subbaramaiah K, Chung WJ, Michaluart P, Telang N, Tanabe T, Inoue H, Jang M, Pezzuto JM, Dannenberg AJ. 1998. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J Biol Chem 273:21875-21882.
49. Sun NJ, Woo SH, Cassady JM, Snapka RM. 1998. DNA polymerase and topoisomerase II inhibitors from Psoralea corylifolia. J Nat Prod 61:362-366.
50. Wang J, Sun L, Myeroff L, Wang X, Gentry LE, Yang J, Liang J, Zborowska E, Markowitz S, Willson JKV, Brattain MG. 1995. Demonstration that mutation of the type II transforming growth factor beta receptor inactivates its tumor suppressor activity in replication error-positive colon carcinoma cells. J Biol Chem 270:22044-22049.
51. Wang J, Han W, Zborowska E, Liang J, Wang X, Willson JKV, Sun L, Brattain MG. 1996. Reduced expression of transforming growth factor beta type I receptor contributes to the malignancy of human colon carcinoma cells. J Biol Chem 271:17366-17371.
52. Yee D, Cullen KJ, Paik S, Perdue JF, Hampton B, Schwartz A, Lippman ME, Rosen N. 1988. Insulin-like growth factor II mRNA expression in human breast cancer. Cancer Res 48:6691-6696.
53. Zugmaier G, Ennis BW, Deschauer B, Katz D, Knabbe C, Wilding G, Daly P, Lippman ME, Dickson RB. 1989. Transforming growth factors type beta 1 and beta 2 are equipotent growth inhibitors of human breast cancer cell lines. J Cell Physiol 141:353-361.